2022
Nonadherence to Multimodality Cancer Treatment Guidelines in the United States
Tchelebi LT, Shen B, Wang M, Potters L, Herman J, Boffa D, Segel JE, Park HS, Zaorsky NG. Nonadherence to Multimodality Cancer Treatment Guidelines in the United States. Advances In Radiation Oncology 2022, 7: 100938. PMID: 35469182, PMCID: PMC9034283, DOI: 10.1016/j.adro.2022.100938.Peer-Reviewed Original ResearchGuideline-concordant treatmentAnal cancerMultimodality treatmentRectal cancerCervical cancerLung cancerAdvanced non-small cell lung cancerNasopharynx cancerNon-small cell lung cancerNonmetastatic anal cancerNational Cancer DatabasePercent of patientsAdvanced cervical cancerCancer treatment guidelinesCell lung cancerMultivariable logistic regressionPrimary tumor siteLow-volume facilitiesTreatment guidelinesComorbid conditionsCancer DatabaseOdds ratioNational guidelinesPatientsConfounding variables
2021
The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases
Salazar MC, Canavan ME, Walters SL, Chilakamarry S, Ermer T, Blasberg JD, Yu JB, Gross CP, Boffa DJ. The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases. JTO Clinical And Research Reports 2021, 2: 100143. PMID: 34590002, PMCID: PMC8474228, DOI: 10.1016/j.jtocrr.2021.100143.Peer-Reviewed Original ResearchStage I NSCLCWedge resectionSurveillance EpidemiologyMortality riskHigh riskSurvival advantageLife expectancyNational Cancer Institute's Surveillance EpidemiologyEnd Results-MedicareTreatment-naive patientsEarly-stage NSCLCRetrospective cohort studySuperior local controlShort life expectancyLife expectancy decreasesPerioperative complicationsCohort studyComorbid conditionsLung parenchymaLobectomyCox modelReasonable optionPatientsNSCLCLocal control